Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Relapse is the main cause of treatment failure for leukaemia patients with unfavourable gene mutations who receive allogeneic haematopoietic stem cell transplantation (allo‐HSCT). There is no consensus on the indication of donor lymphocyte infusion (DLI) for prophylaxis of relapse after allo‐HSCT. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Rui, Wang, Lili, Chen, Peng, Gao, Xiaoning, Wang, Shuhong, Li, Fei, Dou, Liping, Gao, Chunji, Li, Yan, Liu, Daihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124122/
https://www.ncbi.nlm.nih.gov/pubmed/33932107
http://dx.doi.org/10.1002/cam4.3763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124122/
https://www.ncbi.nlm.nih.gov/pubmed/33932107
http://dx.doi.org/10.1002/cam4.3763

Ejemplares similares